Discrimination between normal hyperplastic and malignant human prostatic tissues by enzymatic profiles

C. B. Brendler, A. L. Follansbee, John Tod Isaacs

Research output: Contribution to journalArticle

Abstract

A relative enzymatic index has been developed which differentiates normal, hyperplastic (BPH) and malignant human prostatic tissues. Enzymatic activities have been calculated at V(max) conditions in 10 normal, 14 PH and 11 carcinoma samples. Five enzymes have been assayed: 1) 5α-reductase, 2) 3α-hydroxysteroid oxidoreductase, 3) 3β-hydroxysteroid oxidoreductase, 4) 17β-hydroxysteroid oxidoreductase and 5) acid phosphatase. The following observations were made when comparing individual enzymatic activities between the 3 tissue groups: 1) mean 5α-reductase activity was lower in carcinoma than in both normal prostate and BPH (p <0.05), 2) mean 3α-hydroxysteroid oxidoreductase and 3β-hydroxysteroid oxidoreductase activities were greater in carcinoma than in BPH (p <0.05) and 3) mean acid phosphatase activity was higher in BPH than in both normal prostate and carcinoma (p <0.01). The absolute enzymatic activities were then expressed as relative activities by dividing each absolute value by the mean value for that enzyme in normal prostatic tissue. Relative enzymatic activities were used to derive the ratio: (5α-reductase x acid phosphatase/3α-HSOR x 3β-HSOR). The mean value of this ratio was statistically different in normal, BPH and carcinoma tissue (P <0.01). The mean value was 3.6 times higher in BPH than in normal tissue, and was 3.8 times higher in normal tissue than in carcinoma. This suggests that BPH and carcinoma diverge in opposite directions biochemically from normal prostatic growth and supports histologic evidence that the 2 neoplastic conditions have a different pathogenesis rather than being part of the same disease spectrum.

Original languageEnglish (US)
Pages (from-to)495-501
Number of pages7
JournalJournal of Urology
Volume133
Issue number3
StatePublished - 1985

Fingerprint

Hydroxysteroids
Oxidoreductases
Carcinoma
Acid Phosphatase
Prostate
Enzymes
Growth

ASJC Scopus subject areas

  • Urology

Cite this

Discrimination between normal hyperplastic and malignant human prostatic tissues by enzymatic profiles. / Brendler, C. B.; Follansbee, A. L.; Isaacs, John Tod.

In: Journal of Urology, Vol. 133, No. 3, 1985, p. 495-501.

Research output: Contribution to journalArticle

@article{966ae23a5ceb4ab0b51e6eef9a67d596,
title = "Discrimination between normal hyperplastic and malignant human prostatic tissues by enzymatic profiles",
abstract = "A relative enzymatic index has been developed which differentiates normal, hyperplastic (BPH) and malignant human prostatic tissues. Enzymatic activities have been calculated at V(max) conditions in 10 normal, 14 PH and 11 carcinoma samples. Five enzymes have been assayed: 1) 5α-reductase, 2) 3α-hydroxysteroid oxidoreductase, 3) 3β-hydroxysteroid oxidoreductase, 4) 17β-hydroxysteroid oxidoreductase and 5) acid phosphatase. The following observations were made when comparing individual enzymatic activities between the 3 tissue groups: 1) mean 5α-reductase activity was lower in carcinoma than in both normal prostate and BPH (p <0.05), 2) mean 3α-hydroxysteroid oxidoreductase and 3β-hydroxysteroid oxidoreductase activities were greater in carcinoma than in BPH (p <0.05) and 3) mean acid phosphatase activity was higher in BPH than in both normal prostate and carcinoma (p <0.01). The absolute enzymatic activities were then expressed as relative activities by dividing each absolute value by the mean value for that enzyme in normal prostatic tissue. Relative enzymatic activities were used to derive the ratio: (5α-reductase x acid phosphatase/3α-HSOR x 3β-HSOR). The mean value of this ratio was statistically different in normal, BPH and carcinoma tissue (P <0.01). The mean value was 3.6 times higher in BPH than in normal tissue, and was 3.8 times higher in normal tissue than in carcinoma. This suggests that BPH and carcinoma diverge in opposite directions biochemically from normal prostatic growth and supports histologic evidence that the 2 neoplastic conditions have a different pathogenesis rather than being part of the same disease spectrum.",
author = "Brendler, {C. B.} and Follansbee, {A. L.} and Isaacs, {John Tod}",
year = "1985",
language = "English (US)",
volume = "133",
pages = "495--501",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Discrimination between normal hyperplastic and malignant human prostatic tissues by enzymatic profiles

AU - Brendler, C. B.

AU - Follansbee, A. L.

AU - Isaacs, John Tod

PY - 1985

Y1 - 1985

N2 - A relative enzymatic index has been developed which differentiates normal, hyperplastic (BPH) and malignant human prostatic tissues. Enzymatic activities have been calculated at V(max) conditions in 10 normal, 14 PH and 11 carcinoma samples. Five enzymes have been assayed: 1) 5α-reductase, 2) 3α-hydroxysteroid oxidoreductase, 3) 3β-hydroxysteroid oxidoreductase, 4) 17β-hydroxysteroid oxidoreductase and 5) acid phosphatase. The following observations were made when comparing individual enzymatic activities between the 3 tissue groups: 1) mean 5α-reductase activity was lower in carcinoma than in both normal prostate and BPH (p <0.05), 2) mean 3α-hydroxysteroid oxidoreductase and 3β-hydroxysteroid oxidoreductase activities were greater in carcinoma than in BPH (p <0.05) and 3) mean acid phosphatase activity was higher in BPH than in both normal prostate and carcinoma (p <0.01). The absolute enzymatic activities were then expressed as relative activities by dividing each absolute value by the mean value for that enzyme in normal prostatic tissue. Relative enzymatic activities were used to derive the ratio: (5α-reductase x acid phosphatase/3α-HSOR x 3β-HSOR). The mean value of this ratio was statistically different in normal, BPH and carcinoma tissue (P <0.01). The mean value was 3.6 times higher in BPH than in normal tissue, and was 3.8 times higher in normal tissue than in carcinoma. This suggests that BPH and carcinoma diverge in opposite directions biochemically from normal prostatic growth and supports histologic evidence that the 2 neoplastic conditions have a different pathogenesis rather than being part of the same disease spectrum.

AB - A relative enzymatic index has been developed which differentiates normal, hyperplastic (BPH) and malignant human prostatic tissues. Enzymatic activities have been calculated at V(max) conditions in 10 normal, 14 PH and 11 carcinoma samples. Five enzymes have been assayed: 1) 5α-reductase, 2) 3α-hydroxysteroid oxidoreductase, 3) 3β-hydroxysteroid oxidoreductase, 4) 17β-hydroxysteroid oxidoreductase and 5) acid phosphatase. The following observations were made when comparing individual enzymatic activities between the 3 tissue groups: 1) mean 5α-reductase activity was lower in carcinoma than in both normal prostate and BPH (p <0.05), 2) mean 3α-hydroxysteroid oxidoreductase and 3β-hydroxysteroid oxidoreductase activities were greater in carcinoma than in BPH (p <0.05) and 3) mean acid phosphatase activity was higher in BPH than in both normal prostate and carcinoma (p <0.01). The absolute enzymatic activities were then expressed as relative activities by dividing each absolute value by the mean value for that enzyme in normal prostatic tissue. Relative enzymatic activities were used to derive the ratio: (5α-reductase x acid phosphatase/3α-HSOR x 3β-HSOR). The mean value of this ratio was statistically different in normal, BPH and carcinoma tissue (P <0.01). The mean value was 3.6 times higher in BPH than in normal tissue, and was 3.8 times higher in normal tissue than in carcinoma. This suggests that BPH and carcinoma diverge in opposite directions biochemically from normal prostatic growth and supports histologic evidence that the 2 neoplastic conditions have a different pathogenesis rather than being part of the same disease spectrum.

UR - http://www.scopus.com/inward/record.url?scp=0021914207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021914207&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 495

EP - 501

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -